L-Ornithine L-aspartate salt
L-Ornithine L-aspartate salt structure
|
Common Name | L-Ornithine L-aspartate salt | ||
|---|---|---|---|---|
| CAS Number | 3230-94-2 | Molecular Weight | 265.264 | |
| Density | N/A | Boiling Point | 308.7ºC at 760 mmHg | |
| Molecular Formula | C9H19N3O6 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 140.5ºC | |
|
Modulation of neural activation following treatment of hepatic encephalopathy.
Neurology 80(11) , 1041-7, (2013) To measure changes in psychometric state, neural activation, brain volume (BV), and cerebral metabolite concentrations during treatment of minimal hepatic encephalopathy.As proof of principle, 22 patients with well-compensated, biopsy-proven cirrhosis of diff... |
|
|
L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis.
J. Gastroenterol. Hepatol. 24(1) , 9-14, (2009) Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-l-aspartate (LOLA) is not frequently used as there are still some reservations about its benefit... |
|
|
A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Liver Int. 30(4) , 574-82, (2010) Hepatic encephalopathy (HE) is a complication of liver disease. Several treatments have been introduced but only L-ornithine-L-aspartate (LOLA) shows proven efficacy. This double-blind, randomized, placebo-controlled trial evaluated the effect of LOLA on post... |
|
|
The treatment of hepatic encephalopathy.
Metab. Brain Dis. 22(3-4) , 389-405, (2007) Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to... |
|
|
Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
Aliment. Pharmacol. Ther. 40(1) , 63-71, (2014) Use of TIPSS is associated with increases in ammonia concentration and hepatic encephalopathy (HE) risk. L-ornithine-L-aspartate (LOLA) is effective in reducing ammonia concentration.To evaluate the effects of LOLA on venous ammonia concentration after TIPSS.... |
|
|
Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.
Metab. Brain Dis. 22(1) , 45-50, (2007) Hepatic encephalopathy (HE) is a common problem after insertion of a trans-jugular intrahepatic portosystemic shunt (TIPS), which may be difficult to manage. We present a case of severe post-TIPS HE unresponsive to high doses of L-ornithine-L-aspartate (LOLA)... |
|
|
Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study.
Clin. Drug Investig. 31(4) , 213-20, (2011) Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an i... |
|
|
Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
J. Coll. Physicians Surg. Pak. 21(11) , 666-71, (2011) To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE).Randomized placebo controlled study.The Aga Khan University Hospital, Karachi in the year 2003-2004.Patients with HE were ... |
|
|
[Fulminate liver failure in a 39-year-old female patient with leukocytosis, unclear fever, and arthralgic pain].
Med. Klin. (Munich.) 102(10) , 846-51, (2007) Fulminate liver insufficiency can have many causes and is a challenge for differential diagnosis.A 39-year-old woman was admitted because of a nonitching macular-papular exanthema on both thighs with spreading to the trunk. In addition, the patient complained... |
|
|
L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
J. Coll. Physicians Surg. Pak. 18(11) , 684-7, (2008) To determine the efficacy of L-ornithine-L-aspartate in treatment of hepatic encephalopathy.Randomized, placebo-controlled trial.Department of Gastroenterology and Hepatology, Sheikh Zayed Hospital, Lahore, from February to August 2005.Cirrhotic patients with... |